For one of Seattle Cancer Care Alliance’s top oncology doctors, over treating and under treating patients is not an option.
“We need to tailor the therapy,” SCCA’s Dr. Ajay Gopal said.
Gopal said physicians are working to provide patients with individualized therapies specific to each diagnosis. His remarks were among the latest groundbreaking findings to surface at the American Society of Hematology in San Diego, a national conference dedicated to the latest research in blood cancers.
Gopal talked about clinical trials he shared with colleagues, including a new immunotherapy trial that could be an effective, lower toxicity option for patients with follicular lymphoma.
Also discussed was an international trial at SCCA led by Gopal, where he is evaluating the use of the immunotherapy drug ibrutinib in patients with follicular lymphoma. He hopes that this will represent yet another low toxicity option for patients in the treatment of the disease, leading to better quality of life.
SCCA seeks breakthroughs in patient-centered care through science and collaboration. Read more on Dr. Gopal and research he provides here.
Join the discussion on Facebook.